REMAP-CAP investigators answer yet another important question related to #COVID19 treatments. Take a look at the infographic for a brief overview of the paper (part 1). Read the full paper 👉 jamanetwork.com/journals/jama/… Dr Lisa Higgins Monash Public Health Monash University #remapcapfamily

Congratulations 👏🏾 to #Uganda 🇺🇬 for declaring the end of the #Ebola outbreak today, less than four months after the confirmation of the first case. x.com/WHOAFRO/status…

New hit-to-lead grants for drugs against malaria, TB, chagas, and visceral leishmaniasis: ghitfund.org/assets/attach/… Compounds must come from a Japanese library, partner with Medicines for Malaria Venture (MMV), Drugs for Neglected Diseases initiative, or TB Alliance. Grants up to 2 years, Intent to Apply deadline = Feb 10th

WHO has issued a rapid risk assessment based on the available data on the Omicron XBB.1.5 variant. Learn more🔗bit.ly/3ICYLDW

Some #SARSCoV2 mutations that confer resistance to Paxlovid have been deposited NCBI & GISAID Initiative science.org/doi/10.1126/sc… Science Translational Medicine "Our findings argue for highly selective use...because extensive, unselective use is expected to rapidly lead to emergence of drug resistance."

This nationwide study suggests that patients with mild covid-19 are at risk for a small number of health outcomes, most of which are resolved within a year from diagnosis bmj.com/content/380/bm…

Good news: In the Northeast where the XBB.1.5 variant now accounts for >75% cases, hospital admissions among seniors have mostly started to decline nytimes.com/interactive/20…

We're recruiting for a Mathematical Modeller in Pharmacokinetics for a Medical Research Council funded project. ✅Research the next generation of newly formulated drugs ✅Progress new approaches to therapy ✅Join a multi-disciplinary team Job spec here: lnkd.in/eqtFay8w

"It’s important to acknowledge that objectively we are in a better place with regard to the virus than we’ve ever been" from @today's NEJM commentary nejm.org/doi/full/10.10…

Approximately 75% of people living with #HepatitisC reside in #LMICs with the majority having limited access to life-saving medication. Find out how the #LONGEVITYProject aims to ease the #HCV burden with #longacting injectable medicines. 👉liverpool.ac.uk/centre-of-exce…

📢We're hiring! A data curator Centre of Excellence for Long-acting Therapeutics for further development & maintenance of open access platforms for tracking global development, patent & regulatory status of long-acting therapeutics & technologies. Details: tinyurl.com/y6psf7kr

Deadline: 02 Feb 2024 You will join an excellent team here P&T_UoL Inst of Systems, Molecular & Integrative Biology, working in collaboration with Lobna & colleagues MedicinesPatentPool, and LEAP. Andrew Owen

Check our paper in ⁦Viruses MDPI⁩ on a hamster infection model with #SARSCoV2 subvariants BA.2.86 and EG.5.1 (the latter is the parent of the JN sub-variants) ⁦KU Leuven⁩ ⁦Statens Serum Institut⁩ MDPI mdpi.com/1999-4915/16/1… mdpi.com/1999-4915/16/1…

🚨 RECRUITMENT NEWS We're looking for a #DataCurator from a relevant field, for maintenance of open access platforms tracking global development, patent & regulatory status of #LongActing therapeutics & technologies. Deadline: 2/2/24. Find out more here 👉liverpool.ac.uk/centre-of-exce…

You're invited! Webinar title: "Voluntary licensing & patent pooling for equitable access to life-saving medicines". To receive joining details, please register here: events.teams.microsoft.com/event/dc871f3b…

I feel quite emotional having listened to David Back summarising 40 years of antiretroviral pharmacology & the history of P&T_UoL University of Liverpool. So much progress to celebrate but also a reminder that people matter more than things. What an inspiration! #AtTheEquatorUG #AntiviralPK

#AntiviralPK challenging and fascinating talk by Adeniyi Olagunju on perinatal considerations for long acting medications. Pregnant & breastfeeding women are a major part of society, must not be neglected and we need to harness the very best science to advance knowledge Wellcome

A warm welcome to Dr Lalitkumar Vora, who is visiting Liverpool to present research on microarray patches at the 25th International Workshop on Clinical Pharmacology. Fantastic workshop! Lalitkumar Vora Sudhaunsh Deshpande University of Liverpool Inst of Systems, Molecular & Integrative Biology Andrew Owen CAMO-Net

It was a fantastic experience presenting a part of my PhD project at the 25th International Workshop on Clinical Pharmacology in Liverpool.The workshop was exceptional attending such engaging sessions was an incredible opportunity.#antiviralPK University of Liverpool Centre of Excellence for Long-acting Therapeutics Andrew Owen